

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

<https://marketpublishers.com/r/C46CBA6264EEN.html>

Date: November 2016

Pages: 80

Price: US\$ 784.00 (Single User License)

ID: C46CBA6264EEN

Abstracts

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodgkin lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.

Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as

Combination therapies;

Radioimmunotherapy (RIT);

Immunotoxins (IT);

Antibody-Drug Conjugates (ADC); and

Chimeric Antigen Receptor (CAR) T-Cells.

This report describes the profiles of 16 different specific and bispecific anti-CD22 immunotherapeutics based on different treatment modalities. The most advanced molecule has been submitted for regulatory approval. Furthermore, the profiles of nine companies active in the development of anti-CD22 immunotherapeutics are presented. This report describes and analyzes the

Target Background & Scientific Rationale

Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

Competitive Landscape

Profiles of Anti-CD22 Immunotherapeutics

Profiles of Companies with CD22-Targeted Immunotherapeutics.

Contents

- Target Background & Scientific Rationale
- Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
- Competitive Landscape
- Profiles of Anti-CD22 Immunotherapeutics
 - Naked antibodies;
 - Radioimmunotherapy (RIT);
 - Immunotoxins (IT);
 - Antibody-Dug Conjugates (ADC); and
 - Chimeric Antigen Receptor (CAR) T-Cells.
- Profiles of Companies with CD22-Targeted Immunotherapeutics.
- References
- ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics

I would like to order

Product name: CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Product link: <https://marketpublishers.com/r/C46CBA6264EEN.html>

Price: US\$ 784.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C46CBA6264EEN.html>